EBR Systems (ASX: EBR) — Company Overview, News & Financial Data
EBR Systems develops the WiSE CRT™ System, the first leadless cardiac pacing device for heart failure, targeting U.S. commercialization.
EBR Systems
EBR Systems is a medical technology company focused on developing and commercializing wireless cardiac stimulation technologies. Its flagship product, the Wireless Stimulation Endocardially (WiSE) System, is designed to deliver leadless left ventricular endocardial pacing for cardiac resynchronization therapy (CRT). The technology addresses limitations of traditional CRT devices, which rely on transvenous leads that can fail or cause complications. By converting ultrasonic energy into electrical pulses, the system coordinates therapy with existing pacing devices to treat patients with heart failure and other cardiac rhythm disorders.
Snapshot
Operations
Products and/or services of EBR Systems
- WiSE System Pacing Technology: An ultra-compact leadless left ventricular endocardial pacing device designed to convert ultrasonic energy into electrical pulses, providing physiological pacing for heart failure patients requiring cardiac resynchronization therapy who cannot be treated with conventional leads.
- Pacing System Integration: An open platform system architecture engineered to seamlessly coordinate cardiac therapy with existing pacing devices, including transvenous pacemakers, cardiac resynchronization therapy systems, and implantable cardioverter-defibrillators installed in patients.
- WiSE-UP Post-Approval Study: A post-approval clinical registry gathering real-world clinical performance and outcome data from heart failure patients receiving commercial implants of the WiSE left ventricular endocardial pacing system across clinical sites.
- U.S. Reimbursement and Commercialization: Commercial market rollout supported by Medicare New Technology Add-on Payment and Transitional Pass-Through reimbursement programs, facilitating hospital adoption and patient access for leadless endocardial pacing therapy.
- Expanded Indications Clinical Evaluation: Clinical trial initiatives exploring expanded application of the WiSE system in specialized patient populations, including patients with adult congenital heart disease and individuals requiring upgrades from conventional cardiac devices.
- Regulatory Compliance and Quality Systems: Operational infrastructure dedicated to maintaining United States Food and Drug Administration regulatory compliance, medical device quality management standards, and manufacturing oversight for implantable cardiac technology components.
EBR Systems executive team
- Mr. Allan Roger Will B.S., M.S.Executive Chairman
- Mr. John Graham McCutcheon B.A., M.B.A.President, CEO & Director
- Mr. Gary W. Doherty B.S.Chief Financial Officer
- Mr. Michael Hendricksen B.S., M.S.Chief Operating Officer
- Dr. N. Parker Willis B.S., M.S., Ph.D.Chief Technology Officer
- Mr. Andrew Shute B.S.Senior Vice President of Business Development
- Ms. Madhuri Bhat B.A., M.B.A.Chief Regulatory Officer
- Dr. Spencer H. Kubo M.D.Chief Medical Officer
- Mr. Erik StrandbergChief Commercial Officer
- Mr. John H. SellersSecretary